<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606773</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-14C</org_study_id>
    <nct_id>NCT02606773</nct_id>
  </id_info>
  <brief_title>&quot;Novo C Plus&quot; Vitamin C Containing Dietary Supplement Bioavailability in Healthy Subjects</brief_title>
  <official_title>Open-label, Randomized Comparator Study for Evaluation the Bioavailability of &quot;Novo C Plus&quot; Vitamin C Containing Dietary Supplement in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novonex Pharma Kft</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Semmelweis University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the bioavailability of &quot;Novo C Plus&quot; vitamin C
      containing dietary supplement compared to licensed vitamin C medications. The novelty of this
      product is the liposomal formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma ascorbic acid concentration area under curve</measure>
    <time_frame>360 minutes</time_frame>
    <description>Plasma ascorbic acid concentration will be measured from peripheral blood samples after 30-45-60-90-120-180-240-300-360 minutes after getting the medication. Area under curve of time - plasma concentration curve will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessed by number of subjects with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine ascorbic acid excretion</measure>
    <time_frame>12 hours</time_frame>
    <description>Urine is collected for 12 hours after taking study drug, and urine ascorbic acid excretion will be calculated: urine ascorbic acod concentration (uM)×collected urine (L).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Vitamin C Deficiency</condition>
  <arm_group>
    <arm_group_label>600 mg Novo C plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of oral 600 mg Novo C plus dietary supplement (contains 600 mg ascorbic acid in liposomal formulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>900 mg Novo C Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 900 mg oral Novo C plus dietary supplement (contains 900 mg ascorbic acid in liposomal formulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg intravenous vitamin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 500 mg intravenous ascorbic acid (Vitamin C 100 mg/ml injection; EGIS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg oral vitamin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 500 mg oral ascorbic acid (Cetebe 500 mg retard capsules; GlaxoSmithKline Consumer Healthcare - GSK Export)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Ascorbic acid in different ways and doses</description>
    <arm_group_label>600 mg Novo C plus</arm_group_label>
    <arm_group_label>900 mg Novo C Plus</arm_group_label>
    <arm_group_label>500 mg intravenous vitamin C</arm_group_label>
    <arm_group_label>500 mg oral vitamin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-65 years old healthy volunteers

          -  body weight &gt;45 kg

          -  body height &gt;150 cm

          -  plasma ascorbic acid at screening &lt;75 µmol/l

          -  signed written informed consent

          -  subject agrees avoid vitamin C containing medications and dietary supplements from
             screening until V0 visit (maximum 15 days)

          -  subject agrees to avoid high activity physical exercise 72 hours prior to V0 visit

        Exclusion Criteria:

          -  confirmed or suspected active infection

          -  liver or renal failure (equal or greater than CKD3)

          -  chronic disease that affects absorption or vitamin C metabolism

          -  severe metabolic disorder

          -  body mass index &gt;35 kg/m2

          -  malabsorption syndrome that affects vitamin C metabolism

          -  heart failure, angina pectoris, ventricular arrhythmias or atrial fibrillation with
             &gt;100/min ventricular rate

          -  gastrointestinal bleeding in past three months

          -  uncontrolled diabetes mellitus (HbA1c&gt;8,5%)

          -  malignant disease

          -  alcohol or drug abuse

          -  active psychiatric disorder, intention for suicidal, disorders with unconsciousness

          -  psychopathic disorder, lack of cooperation

          -  known coagulopathy

          -  chronic obstructive lung disease or active smoking (more than 2 cigarettes in the past
             6 months)

          -  untreated hypertension if blood pressure is greater than 165/95 mmHg

          -  gravidity or breastfeeding

          -  taking more than 100 mg vitamin C daily within 2 weeks to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Semmelweis University - 1st Departement of Internal Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Semmelweis University</investigator_affiliation>
    <investigator_full_name>Istvan Takacs</investigator_full_name>
    <investigator_title>Reader in university</investigator_title>
  </responsible_party>
  <keyword>vitamin C supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid Deficiency</mesh_term>
    <mesh_term>Scurvy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

